Fred Aslan, Artiva

Mer­ck part­ner Arti­va blue­prints San Diego R&D, man­u­fac­tur­ing site to take NK cell op­er­a­tion to the next lev­el

In Jan­u­ary, Arti­va Bio­ther­a­peu­tics CEO Fred Aslan said his com­pa­ny is look­ing to cre­ate CAR-NK ther­a­pies with best-in-class ef­fi­ca­cy made in a whol­ly owned man­u­fac­tur­ing process. Arti­va is now an­oth­er step clos­er to that goal.

Arti­va will open a 52,000 square-foot head­quar­ters in San Diego that will house its R&D and man­u­fac­tur­ing of NK cell ther­a­pies. The site will have a mul­ti-suite, cus­tom-built man­u­fac­tur­ing fa­cil­i­ty up to cur­rent GMP stan­dards and adds to its cur­rent man­u­fac­tur­ing op­er­a­tions at GC Lab­Cell’s 300,000-square-foot lo­ca­tion in South Ko­rea. This new site won’t re­place what’s go­ing on in Ko­rea but dou­ble down on the amount of ca­pac­i­ty the com­pa­ny has.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.